Cardinal Health (CAH) Soars 1.51% on Morgan Stanley Price Target Hike

Cardinal Health (CAH) surged to a record high today, with an intraday gain of 1.51%.

The strategy of buying CAH shares after they reached a recent high and holding for 1 week showed poor performance over the past 5 years. The annualized return was -1.7%, significantly underperforming the market. This indicates that relying solely on recent highs as a buying trigger and holding for a short duration is not a reliable strategy for CAH, leading to underwhelming returns.

On June 13, 2025, Morgan Stanley announced an increase in the price target for Cardinal Health (CAH), which is the most relevant reason for the change in the stock price. The analyst maintained an "Overweight" rating for CAH and raised the price target from $166.00 to $181.00. This adjustment reflects a positive outlook on the company's future performance, indicating increased confidence in Cardinal Health's growth prospects and market position. This news is likely to influence investor sentiment and the stock's market trajectory.